Company Analysis

Allogene Therapeutics, Inc. (ALLO)

Nasdaq: ALLO · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2018
Grade3.7
◀ Past 3.1● Present 4.9▶ Future 3.1
4 est.

Who runs Allogene Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Roberts Zachary
President and CEO. First filing Jan 2023, latest Jul 6, 2026, 4 filings in all.
Officers reporting now
6
of 14 people with a filing in the last fifteen months
Directors reporting now
8
25 people on the record since 2018
Officerssales are open-market, Oct 23, 2025 to Oct 23, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Parker Geoffrey M.CHIEF FINANCIAL OFFICEROct 2023Oct 23, 20262 · $100,000
Douglas Earl MartinSVP, General CounselAug 2023Aug 25, 20262 · $100,000
Roberts ZacharyPresident and CEOJan 2023Jul 6, 20262 · $100,000
Yoshiyama AnnieSVP, FinanceJun 2024Apr 23, 20262 · $0.00
Beneski Benjamin MachinasSVP, Chief Technical OfficerMar 2025Apr 2, 20265 · $100,000
Chang David DPresident and CEOOct 2018Mar 18, 20262 · $300,000
Directorssales are open-market, Oct 23, 2025 to Oct 23, 2026
NameRoleFirst filingLatest filingSales, 12 months
Barrett Elizabeth A.directorAug 2021Jun 23, 2026none
Humer Franz BdirectorOct 2018Jun 23, 2026none
Kazam Joshua AdirectorOct 2018Jun 23, 2026none
Mayo StephendirectorJul 2022Jun 23, 2026none
Messemer Deborah M.directorOct 2018Jun 23, 2026none
Sato Vicki LdirectorJul 2021Jun 23, 2026none
Witte Owen N.directorOct 2018Jun 23, 2026none
Belldegrun AriedirectorOct 2018Feb 4, 2026none
Earlier names on the record16, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ALLO · research, not advice